EDP Sciences logo
Subscriber Authentication Point
rechercher
Menu
Accueil Tous les numéros Volume 212 / Numéro 3-4 (2018) Biologie Aujourd'hui, 212 3-4 (2018) 61-67 References
Free Access
Issue
Biologie Aujourd'hui
Volume 212, Number 3-4, 2018
Page(s) 61 - 67
DOI https://doi.org/10.1051/jbio/2019011
Published online 11 avril 2019
  • André, P., Denis, C., Soulas, C., Bourbon-Caillet, C., Lopez, J., Arnoux, T., Bléry, M., Bonnafous, C., Gauthier, L., Morel, A., Rossi, B., Remark, R., Breso, V., Bonnet, E., Habif, G., Guia, S., Lalanne, A.I., Hoffmann, C., Lantz, O., Fayette, J., Boyer-Chammard, A., Zerbib, R., Dodion, P., Ghadially, H., Jure-Kunkel, M., Morel, Y., Herbst, R., Narni-Mancinelli, E., Cohen, R.B., Vivier, E. (2018). Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell , 175, 1731-1743 e1713. [Google Scholar]
  • Benson, D.M., Jr., Bakan, C.E., Zhang, S., Collins, S.M., Liang, J., Srivastava, S., Hofmeister, C.C., Efebera, Y., André, P., Romagne, F., Bléry, M., Bonnafous, C., Zhang, J., Clever, D., Caligiuri, M.A., Farag, S.S. (2011). IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood , 118, 6387-6391. [CrossRef] [Google Scholar]
  • Carlsten, M., Korde, N., Kotecha, R., Reger, R., Bor, S., Kazandjian, D., Landgren, O., Childs, R.W. (2016). Checkpoint inhibition of KIR2D with the monoclonal antibody IPH2101 induces contraction and hyporesponsiveness of NK cells in patients with myeloma. Clin Cancer Res , 22, 5211-5222. [CrossRef] [PubMed] [Google Scholar]
  • Chen, D.S., Mellman, I. (2017). Elements of cancer immunity and the cancer-immune set point. Nature , 541, 321-330. [CrossRef] [PubMed] [Google Scholar]
  • Childs, R.W., Carlsten, M. (2015). Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: The force awakens. Nat Rev Drug Discov , 14, 487-498. [CrossRef] [PubMed] [Google Scholar]
  • Daeron, M., Jaeger, S., Du Pasquier, L., Vivier, E. (2008). Immunoreceptor tyrosine-based inhibition motifs: A quest in the past and future. Immunol Rev , 224, 11-43. [CrossRef] [PubMed] [Google Scholar]
  • Guillerey, C., Huntington, N.D., Smyth, M.J. (2016). Targeting natural killer cells in cancer immunotherapy. Nat Immunol , 17, 1025-1036. [CrossRef] [PubMed] [Google Scholar]
  • Imai, K., Matsuyama, S., Miyake, S., Suga, K., Nakachi, K. (2000). Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: An 11-year follow-up study of a general population. Lancet , 356, 1795-1799. [CrossRef] [PubMed] [Google Scholar]
  • Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., Minato, N. (2002). Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA , 99, 12293-12297. [Google Scholar]
  • Kohrt, H.E., Thielens, A., Marabelle, A., Sagiv-Barfi, I., Sola, C., Chanuc, F., Fuseri, N., Bonnafous, C., Czerwinski, D., Rajapaksa, A., Waller, E., Ugolini, S., Vivier, E., Romagne, F., Lévy, R., Bléry, M., André, P. (2014). Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood , 123, 678-686. [CrossRef] [Google Scholar]
  • Mamessier, E., Sylvain, A., Thibult, M.L., Houvenaeghel, G., Jacquemier, J., Castellano, R., Goncalves, A., André, P., Romagne, F., Thibault, G., Viens, P., Birnbaum, D., Bertucci, F., Moretta, A., Olive, D. (2011). Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest , 121, 3609-3622. [CrossRef] [PubMed] [Google Scholar]
  • Orange, J.S., Ballas, Z.K. (2006). Natural killer cells in human health and disease. Clin Immunol , 118, 1-10. [CrossRef] [PubMed] [Google Scholar]
  • Pesce, S., Greppi, M., Tabellini, G., Rampinelli, F., Parolini, S., Olive, D., Moretta, L., Moretta, A., Marcenaro, E. (2017). Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization. J Allergy Clin Immunol , 139, 335-346 e3. [CrossRef] [Google Scholar]
  • Platonova, S., Cherfils-Vicini, J., Damotte, D., Crozet, L., Vieillard, V., Validire, P., André, P., Dieu-Nosjean, M.C., Alifano, M., Régnard, J.F., Fridman, W.H., Sautes-Fridman, C., Cremer, I. (2011). Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res , 71, 5412-5422. [CrossRef] [Google Scholar]
  • Romagne, F., André, P., Spee, P., Zahn, S., Anfossi, N., Gauthier, L., Capanni, M., Ruggeri, L., Benson, D.M., Jr., Blaser, B.W., Della Chiesa, M., Moretta, A., Vivier, E., Caligiuri, M.A., Velardi, A., Wagtmann, N. (2009). Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood , 114, 2667-2677. [CrossRef] [PubMed] [Google Scholar]
  • Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W.D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., Martelli, M.F., Velardi, A. (2002). Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science , 295, 2097-2100. [CrossRef] [Google Scholar]
  • Ruggeri, L., Mancusi, A., Burchielli, E., Capanni, M., Carotti, A., Aloisi, T., Aversa, F., Martelli, M.F., Velardi, A. (2008). NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. Blood Cells Mol Dis , 40, 84-90. [CrossRef] [PubMed] [Google Scholar]
  • Ruggeri, L., Urbani, E., André, P., Mancusi, A., Tosti, A., Topini, F., Bléry, M., Animobono, L., Romagne, F., Wagtmann, N., Velardi, A. (2016). Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells. Haematologica , 101, 626-633. [CrossRef] [PubMed] [Google Scholar]
  • Talebian Yazdi, M., van Riet, S., van Schadewijk, A., Fiocco, M., van Hall, T., Taube, C., Hiemstra, P.S., van der Burg, S.H. (2016). The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma. Oncotarget , 7, 3477-3488. [PubMed] [Google Scholar]
  • Tursz, T., Dokhelar, M.C., Lipinski, M., Amiel, J.L. (1982). Low natural killer cell activity in patients with malignant lymphoma. Cancer , 50, 2333-2335. [CrossRef] [PubMed] [Google Scholar]
  • Vivier, E., Raulet, D.H., Moretta, A., Caligiuri, M.A., Zitvogel, L., Lanier, L.L., Yokoyama, W.M., Ugolini, S. (2011). Innate or adaptive immunity? The example of natural killer cells. Science , 331, 44-49. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.